<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of this study was to evaluate the detection rate of chromosomal rearrangements in <z:hpo ids='HP_0001909'>leukemia</z:hpo> using single nucleotide polymorphism array (SNP-A) in combination with metaphase cytogenetics (MC), with the aim of proposing a practical approach for clinical karyotyping applications of SNP-A </plain></SENT>
<SENT sid="1" pm="."><plain>The Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA) was applied in 469 patients with a variety of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Combined use of SNP-A with MC improved the detection rate in comparison with MC alone: <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) with <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype (NK), 32% versus 0%; core binding factor (CBF)-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> 40% versus 29%; <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 54% versus 39%; <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 24% versus 3%; and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), 88% versus 63% </plain></SENT>
<SENT sid="3" pm="."><plain>Different patterns of abnormalities (especially the type, size, and location) were noted in the <z:hpo ids='HP_0001909'>leukemia</z:hpo> subtypes </plain></SENT>
<SENT sid="4" pm="."><plain>Copy neutral loss of heterozygosity lesions was detected in 23% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-NK, 3% of CBF-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 25% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 2% of <z:mp ids='MP_0005481'>CML</z:mp>, and 20% of ALL </plain></SENT>
<SENT sid="5" pm="."><plain>SNP-A also provided information on cryptic deletions and a variety of <z:mp ids='MP_0004024'>aneuploidies</z:mp> in ALL, while the benefit was minimal in <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, different patterns of abnormal lesions were presented according to the disease category, thus requiring a different approach of adopting SNP-A-based karyotyping among different <z:hpo ids='HP_0001909'>leukemia</z:hpo> subtypes </plain></SENT>
</text></document>